What they were paid
Maze Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $54,076 | — | $294,907 | $0 | $348,983 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Maze Therapeutics, Inc. DEF 14A filed April 28, 2026, accession 0001140361-26-017463, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Maze Therapeutics pays directors a $40,000 cash retainer and $750,000 in Options.
Committees
FY2025 · as the proxy prints themAudit (Chair) · Compensation · Nominating/Governance
The rest of the Maze Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Catherine Angell Sohn, Pharm.D | Independent Director | $343,657 |
| Charles Homcy, M.D | Director | $602,065 |
| Hervé Hoppenot | Chair of the Board | $738,726 |
| Jason Coloma, Ph.D | Director | $0 |
| Jeffrey Tong | Independent Director | $0 |
| Jonathan Lim, M.D | Independent Director | $344,240 |
| Nancy C. Andrews, M.D., Ph.D | Independent Director | $345,490 |
| Neil Exter | Independent Director | $488,674 |
| Neil Kumar, Ph.D | Independent Director | $0 |
| Richard Scheller, Ph.D | Independent Director | $405,907 |
| Sekar Kathiresan | Independent Director | $364,678 |
The full Maze Therapeutics compensation record
free company briefThis page is one director within Maze Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat